# Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

> **NCT07004335** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 40 (estimated)

## Conditions studied

- PD-(L)1
- CTLA-4
- Advanced Melanoma
- Iparomlimab
- Tuvonralimab
- Bevacizumab

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab Injection plus Bevacizumab

## Key facts

- **NCT ID:** NCT07004335
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07004335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07004335, "Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07004335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*